|
|
CytRx Corporation - Comparative Business Analysis Snapshot
Business Description
CytRx Corporation. The Group's principal activity is developing and commercializing pharmaceutical products. It is involved in the development of novel small molecules based on molecular 'chaperone' co-induction technology, with broad therapeutic applications in neurology, diabetes and cardiology. Products are used for treatment of obesity, type 2 diabetes and human cytomegalovirus.
Competitor Analysis
This analysis compares CytRx Corporation with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
